This page shows the latest AB-506 news and features for those working in and with pharma, biotech and healthcare.
A combination study of AB-506 and AB-729 was due to start next year but now won’t go ahead. ... Arbutus’ other candidates in development for HBV include follow-on oral capsid inhibitors that have different chemical structures, so may avoid the
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...